CorVel vs Marsh & McLennan Companies: Fair Value & Quality
Both stocks run through our valuation models. Here is how CorVel (CRVL) and Marsh & McLennan Companies (MRSH) compare, as of Aug 10, 2026.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Marsh & McLennan Companies leads: 4 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
CorVel
4 of 4 models see the stock below the current price.
Marsh & McLennan Companies
6 of 6 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
CorVel · Health Care
Marsh & McLennan Companies · Financials
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees CorVel as the less overvalued of the two: CorVel trades at $62.56 versus a fair value of $47.59 (-24%), while Marsh & McLennan Companies trades at $192 versus $112 (-41%).
CorVel has the higher quality score (67/100).
See the full analysis →More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Related to CorVel
Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & CompanyRelated to Marsh & McLennan Companies
Alphabet Inc Class C vs Verizon CommunicationsAlphabet Inc Class C vs At&tAlphabet Inc Class C vs NetEaseAmazon.com vs Toyota Motor CorporationSee the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.